IAMA Therapeutics

IAMA Therapeutics is a private, clinical-stage biotech company pioneering a novel approach to treating central nervous system (CNS) disorders through the selective inhibition of cation-chloride cotransporters, with a primary focus on NKCC1. The company, a spin-off from the Istituto Italiano di Tecnologia, has secured significant funding (€15M in 2025) and is led by an experienced CEO, Torsten M. Madsen, appointed in late 2025. IAMA's strategy is to restore neuronal balance by modulating chloride transport, targeting high-unmet-need conditions like autism and epilepsy where current treatments are often inadequate.

Platform for developing selective small molecule inhibitors of cation-chloride cotransporters (CCCs), primarily NKCC1, to modulate neuronal chloride balance and restore inhibitory tone in the central nervous system.

Competition includes other companies targeting neuronal excitability through ion channels or GABA modulation, as well as developers of generic and novel anti-epileptics. IAMA's specific focus on NKCC1 inhibition is relatively differentiated, but it may face competition from companies developing KCC2 enhancers, which aim to achieve a similar net effect on chloride balance. Large pharma with neurology divisions are potential competitors or partners.